54 results about "Macrogol" patented technology

The invention discloses a vitamin D3-polyethylene glycol composition and a preparation method thereof, the vitamin D3-polyethylene glycol composition comprises vitamin D3, a dispersion medium, an adsorbent and polyethylene glycol, the vitamin D3 is dissolved in the dispersion medium, the adsorbent is used for adsorption, and then the mixture is added into hot-melt polyethylene glycol for dispersion to obtain the vitamin D3-polyethylene glycol composition. The dosage of the polyethylene glycol is controlled to be 70%-90% of that of the vitamin D3-polyethylene glycol composition; the vitamin D3 in the calcium carbonate / vitamin D3 pharmaceutical composition prepared by the invention has excellent long-term stability, and also has good mixing uniformity and content uniformity; the preparation process is simple, the vitamin D3 and other auxiliary materials do not need to be prepared into large particles in advance, the particles are easy to transfer without freeze-drying, the material loss is less, and the preparation method is suitable for industrialization.

The invention relates to a rapid setting liquid lung sealant that forms a highly adherent and elastic hydrogel. Provided are lung sealants comprising two high molecular weight (20 kDa) multi-arm PEG compositions wherein the first PEG composition includes an alkaline buffer and the second PEG composition includes a mildly acidic buffer for optimized set up time and extended working time. In some embodiments, the PEGs further comprise a radioprotectant such as tocopherol. In some embodiments, a colorant is added to one or both PEGs of the lung sealant to improve visualization of the lung sealant against human lung tissue.

Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.

The present invention concerns methods comprising co-administration of pegfilgrastim and romiplostim for treatment of diseases and conditions characterized by low neutrophil levels (neutropenia) and / or low platelet levels (thrombocytopenia). The present invention concerns an enhanced effect on neutrophil levels and on platelet levels resulting from co-administration of pegfilgrastim and romiplostim. The present invention further concerns a method of treating a patient who has been exposed to radiation, which comprises administering romiplostim at a dose of about 1 to about 10 g / kg. The invention further concerns such methods wherein a single dose of romiplostim is administered to the patient and wherein romiplostim is administered about 24 hours or less after the radiation exposure. The invention further concerns treatment with romiplostim and pegfilgrastim for radiation exposure. Such methods relate to treatment of acute radiation syndrome and treatment to counteract the effects of radiation therapy and other sources of radiation exposure.

The invention discloses an application of gelatinized intestinal epithelial cells in preparation of drugs for treating inflammatory bowel disease, the gelatinized intestinal epithelial cells take mouse intestinal epithelial cells as cores, poly (ethylene glycol) diacrylate, a photoinitiator and poly-L-lysine permeate into the cells through low-temperature freeze thawing, and an intracellular porous hydrogel skeleton is formed through ultraviolet crosslinking. The gelated intestinal epithelial cell has a strong cfDNA and inflammatory factor removal function, has good biocompatibility, has no direct or indirect toxic effect on a human body, has no potential toxicity, and can be used for treating inflammatory bowel diseases.

The invention belongs to the technical field of biological medicine, and relates to a releasable pegylated sirolimus compound and application thereof. The invention provides a releasable PEGylated sirolimus compound. The compound can be self-assembled to form micelles, prepared into nanoparticles and targeted to immune cells, regulates the release behavior of drugs, reduces the system toxicity and prolongs the biological half-life period. And moreover, the sirolimus-hydrophilic PEG conjugate has a proper hydrophobic sirolimus end and a hydrophilic PEG chain end, can effectively release drugs in immune cells, and is a good carrier for preparing nanoparticles. The invention provides a releasable PEGylated sirolimus compound, a nano-drug and a pharmaceutical composition prepared from the releasable PEGylated sirolimus compound, and application of the releasable PEGylated sirolimus compound in preparation of drugs for reducing immune response.

Provided herein are methods for treating cancer comprising administering to a subject in need thereof an adamantane derivative, or a pharmaceutically acceptable salt thereof, such as rimantadine or amantadine. In some embodiments, the adamantane derivative is PEGylated.

The invention relates to a rapid setting liquid lung sealant that forms a highly adherent and elastic hydrogel. Provided are lung sealants comprising two high molecular weight (20 kDa) multi-arm PEG compositions wherein the first PEG composition includes an alkaline buffer and the second PEG composition includes a mildly acidic buffer for optimized set up time and extended working time. In some embodiments, the PEGs further comprise a radioprotectant such as tocopherol. In some embodiments, a colorant is added to one or both PEGs of the lung sealant to improve visualization of the lung sealant against human lung tissue.

The invention relates to a composite nano-system, a preparation method and application, the composite nano-system is a lipid-polymer hybrid nanoparticle with a core-shell structure, and the composite nano-system comprises: a hydrophobic core which is composed of a biodegradable polymer and cholesterol and is encapsulated with a hydrophobic drug formononetin; the middle layer is composed of cation / ionized lipid and auxiliary lipid and is used for loading negatively charged anti-KRAS siRNA through electrostatic interaction to form a stable compound, and the stable compound and the hydrophobic core jointly form nanoparticles; the shell layer is composed of pegylated lipid and a targeting ligand, and the targeting ligand is tLyp-1 peptide and is covalently linked to the tail end of the pegylated lipid through a maleimide-sulfydryl click chemical reaction. The system has excellent stability, biocompatibility and tumor targeting ability, can synergistically inhibit the growth of KRAS mutation pancreatic cancer, and relates to an application of the system in preparation of drugs for treating such cancers.

To provide poly (amine-co-ester) polymers, methods of forming polyplexes and particles loaded with active agents therefrom, and methods of using them for delivery of nucleic acid agents with optimal uptake.SOLUTION: The examples demonstrate important molecular weights in combination with exposed carboxylic acid and / or hydroxyl groups, and methods of making. Typically, the composition is less toxic, more efficient in drug delivery, or a combination thereof, as compared to other transfection reagents in the control. In some embodiments, the composition is suitable for invivo delivery and can be administered systemically to a subject to treat a disease or condition. In vivo delivery to the lung by inhalation has been demonstrated for poly (amine-co-ester) polymers having certain amine or hydroxyl group-containing end groups during mixing with PEGylated poly (amine-co-ester) polymers.SELECTED DRAWING: None

Provided are relating to pulmonary delivery of mRNA as inhaled dry powder formulation and compositions comprising the mRNA; also provided are methods of using and making the composition.

The invention provides a compound external preparation for promoting rash healing and a preparation method thereof, and aims to solve the problems of single target spot, low delivery efficiency, obvious stimulation and easy relapse of the existing rash preparation. The preparation comprises four groups of core active components of antimicrobial, anti-inflammatory and antipruritic, immunoregulation and tissue repair, and is matched with a skin micro-ecological regulator and an antagonist to construct an antibacterial, anti-inflammatory, repair and anti-recurrence full-chain treatment system; liposome formed by negatively charged phospholipid and pegylated cholesterol is used as a carrier and is combined with an azone-propylene glycol composite penetration enhancer, so that the transdermal efficiency and stability of active ingredients are improved; a step-by-step drug loading process is adopted for preparation, differentiated loading is performed according to physicochemical properties of components, and curative effect fluctuation is avoided; the preparation is suitable for various rash types, is non-irritant and anti-relapse, the process is controllable and easy to scale, and an efficient and safe scheme is provided for rash treatment.

Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise DSPE-peg2000 and nosiheptide in a molar ratio of 3:1. Compositions and methods which is related to making the PEGylated liposomes and using the PEGylated liposomes for preventing or treating bacterial infection are also provided.

A preparation of PEGylated solid lipid core nanocarriers (SLN) is loaded with at least one drug for delivery to a subject. SLNs having a small size, neutral charge, and high drug encapsulation efficiency are formed. PEGylation improves SLN permeability without hindering cellular uptake, particularly permeability of nasal mucous for intranasal delivery. PEGylated SLNs are suitable for intranasal, inhaled, oral or injected drug delivery. Exemplary formulations include a combined antiretroviral therapy (cART) designed to cross the blood-brain barrier and treat neuroAIDS.

The invention provides a nano preparation for preparing a medicine for inhibiting prostatic cancer and a preparation method of the nano preparation, and relates to the technical field of nano medicinal preparations. The nano preparation comprises the following components in parts by mass: traditional Chinese medicine components and a nano carrier, the traditional Chinese medicine component comprises 15-45 parts of a Chinese yam extract, 5-15 parts of a madder extract, 8-20 parts of cuttlebone superfine powder, 10-25 parts of dragon bone superfine powder and 10-25 parts of oyster superfine powder; the nano-carrier comprises 5-20 parts of phospholipid, 2-10 parts of cholesterol, 1-5 parts of fatty acid, 3-15 parts of polyethylene glycol and 1-5 parts of a surfactant. The average particle size of the nano preparation is 80-150 nm, the polydispersity index PDI is smaller than or equal to 0.30, and the encapsulation efficiency is larger than or equal to 75%. According to the invention, active ingredients of traditional Chinese medicines are combined with a nanotechnology, so that the bioavailability and the tumor targeting property are remarkably improved, the pH-responsive release characteristic is achieved, a remarkable inhibition effect on various prostate cancer cell lines is shown, tumor growth can be effectively inhibited, metastasis can be reduced, and a good application prospect is achieved.

A method to treat cartilage and peri-cartilage is provided which utilizes a pseudoplastic scaffold comprising a PEGylated protein-containing microgel and a hydrolyzed collagen component. The pseudoplastic scaffold composition can be applied topically, via injection, or via ingestion.

SULFATE- AND PEG-FREE CLEANSING COMPOSITION WITH HIGH SALICYLIC ACID CONTENT. A cleansing composition is intended for cleansing the skin in a rinse-off formulation that provides a stable disposition of an acne treatment active, for example, a beta-hydroxy acid, on the skin that resists removal by rinsing with or without the use of a cleansing device. The cleansing composition includes at least one beta-hydroxy acid, for example, salicylic acid or one of its derivatives, which is present in an amount greater than 1%, by weight, relative to the weight of the cleansing composition, and an aqueous carrier that includes lauryl lactate for thickening and stabilization, at least one surfactant, at least one cationic agent, and optional additives.The cleansing formula produces a pleasant, high lather, is free of sulfates and drying, irritating PEG-type components, demonstrates phase stability for at least three months at temperatures up to 45°C, and demonstrates retention of the beta-hydroxy acid active ingredient on the skin after cleansing and rinsing. Figure for the summary: none.

The application discloses a preparation method of an in-situ hydrazone bond injectable hydrogel and application thereof to preventing abdominal cavity adhesion, and belongs to the field of medical biomaterials. The application takes 8-arm-PEG10000-CHO with an aldehyde group at a terminal and 8-arm-PEG10000-HZ with a hydrazine group at a terminal as raw materials, forms a hydrazone bond through a Schiff base reaction, and obtains PCA supermolecular hydrogel through in-situ construction; the preparation method of the application does not need a chemical crosslinking agent, can quickly form a gel at room temperature, is simple and controllable in process, and the prepared hydrogel has excellent injectability, self-healing performance, biodegradability and biocompatibility, can form a stable physical barrier in-situ on an abdominal surgery wound, effectively inhibits inflammatory cell infiltration and collagen fiber deposition, has a significant prevention effect on light, medium and severe abdominal cavity adhesion, and especially still has excellent protection capability in a severe inflammatory adhesion model induced by talc, thereby providing a safe and effective new scheme for preventing and treating postoperative abdominal cavity adhesion.

A method of treating Arginase 1 (ARG1) deficiency (ARG1-D) in a subject, comprising administering a pegzilarginase to the subject, wherein the pegzilarginase is a pegylated human arginase 1 comprising a cobalt metal cofactor, and wherein the pegzilarginase is administered weekly at a dose of from about 0.05 mg / kg to about 0.2 mg / kg.

The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.

The invention discloses a seed dressing agent and a preparation method thereof. Comprising 30-50 parts of a chaetomium globosum QM bacterial agent, 30-50 parts of an enterobacter chinense 314 A1 bacterial agent, 20-40 parts of chitosan, 5-10 parts of a film-forming agent and 3-8 parts of a wetting dispersant. According to the seed dressing agent disclosed by the invention, the chaetomium globosum QM bacterial agent and the enterobacter chinense 314 A1 bacterial agent are added, so that the seedling rate and the growth condition of tomato seedlings are improved, and a synergistic interaction effect is achieved by combined use of the bacterial agent and the enterobacter chinense 314 A1 bacterial agent. By using the polylactic acid-polyethylene glycol copolymer and locust bean gum composite film-forming agent and the nekal and polyethylene glycol monohexadecyl ether composite wetting dispersant, the germination rate of the tomato seeds is increased, and synergistic interaction is achieved.

The application provides a supercritical CO2 assisted preparation of quercetin nanoparticles and application thereof to resisting gastric cancer stem cells. The nanoparticles are prepared by encapsulating quercetin with polylactic acid-co-ethylene glycol (PLGA), so as to solve the problems of poor water solubility and low bioavailability of quercetin and improve the inhibiting effect of quercetin on gastric tumor stem cells. Through a specific preparation process, quercetin-PLGA nanoparticles (Qu-PLGA NS) with uniform particle size and uniform dispersion are obtained. Experimental results show that the Qu-PLGA NS can effectively inhibit the growth and proliferation of gastric tumor stem cells, induce apoptosis of the gastric tumor stem cells, and significantly reduce the invasion and metastasis ability of the gastric tumor stem cells. In addition, the nanoparticles can also reverse the multi-drug resistance of the gastric tumor stem cells, improve the curative effect of a chemotherapeutic drug, and reduce side effects. The application provides a new idea and method for the treatment of gastric cancer and has important clinical application value.

The invention relates to the technical field of nano-drug delivery of biological medicine, in particular to a folic acid modified kaempferol-loaded targeted nano-liposome as well as a preparation method and application thereof, the folic acid modified kaempferol-loaded targeted nano-liposome comprises phospholipid, cholesterol, pegylated lipid, kaempferol and a pegylated lipid-folic acid conjugate; the preparation method comprises the following steps: dissolving phospholipid, cholesterol, pegylated lipid and kaempferol in a volatile organic solvent to obtain a mixed solution; preparing the mixed solution into a lipid film; the preparation method comprises the following steps: performing targeted modification on a lipid film by using a pegylated lipid-folic acid conjugate to obtain a folic acid modified kaempferol-loaded targeted nano-liposome; the kaempferol can be applied to preparation of drugs for treating diabetic kidney diseases, and the problems that when kaempferol is applied in vivo, solubility is low, bioavailability is poor, renal tubule targeting is lacked, and common nano-carriers are insufficient in targeting and stability are solved.

An injectable and temperature-responsive enhanced composite dual-network magnetic particle gel is a hydrogel, including a particle gel network formed by gelatin nanoparticles and Fe3O4 nanoparticles via an electrostatic interaction and a poly(N-isopropylacrylamide) (PNIPAM)-based temperature-sensitive polymer gel network. At room temperature, the hydrogel exhibits excellent shear-thinning and self-healing properties, and is easily injectable through needles and microcatheters. When raised to a human body temperature (37° C.), the temperature-sensitive polymer undergoes phase transition cross-linking, enhancing mechanical properties of the gel network. The hydrogel is injectable in vitro and exhibits temperature-responsive strengthening in vivo, meeting the requirements of a vascular interventional embolization material. The hydrogel can also generate magnetothermal heating under an alternating magnetic field, thereby achieving the embolization combined with magnetothermal therapy for liver cancer. The preparation method is simple, with high biocompatibility and a great potential for clinical applications.

Provided herein are GRFT variants and methods of using such GRFT variants. The GRFT variants described herein can be PEGylated, which significantly improves the pharmacokinetics and decreases the immunogenicity of the GFRT composition.

The invention discloses a low-cytotoxicity d-limonene nanoemulsion for preventing oral cancer. The low-cytotoxicity d-limonene nanoemulsion comprises the following components: 0.4-10% of d-limonene, 0.1-5% of tea tree oil, 0.25-5% of an oil phase, 1-15% of a surfactant, 1-5% of a cosurfactant and the balance of deionized water or distilled water, wherein the surfactant is a mixture of caprylic / capric polyethylene glycol glyceride and polyoxyethylene hydrogenated castor oil RH-40; and the cosurfactant is PEG (Polyethylene Glycol)-400. CCK8, Calcein-AM / PI cell live and dead double staining experiments and animal model verification prove that the nano-emulsion formed by the caprylic / capric polyethylene glycol glyceride / RH-40 / PEG-400 composite surfactant and the d-limonene / tea tree oil has lower cytotoxicity than the nano-emulsion prepared from Tween-80; the invention provides a safer and more effective novel preparation for preventing and treating oral precancerous lesions.